» Articles » PMID: 34314672

Hospitalization Risk for Medicare Beneficiaries With Nontuberculous Mycobacterial Pulmonary Disease

Overview
Journal Chest
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2021 Jul 27
PMID 34314672
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Nontuberculous mycobacterial pulmonary disease (NTM-PD) is an uncommon mycobacterial infection characterized by worsening lung function and increased health care resource utilization; however, the overall risk for hospitalization among patients with NTM-PD remains unclear.

Research Question: What is the hospitalization risk among older adults with NTM-PD?

Study Design And Methods: A retrospective, nested, case-control study was conducted by using the Medicare claims database. Cases were defined as patients with ≥ 2 NTM-PD claims ≥ 30 days apart between January 1, 2007, and December 31, 2015. The study included individuals aged ≥ 65 years with ≥ 12 months of continuous enrollment in both Parts A and B before the first NTM-PD diagnosis. Cases were matched 1:2 to Medicare beneficiaries without NTM-PD (control subjects) according to age and sex. Hospitalizations following the first NTM-PD claim were compared between case and control subjects by using univariate and multivariate analyses.

Results: A total of 35,444 case subjects and 65,467 matched control subjects (mean age, 76.6 years; 70% female; ≥ 87% White) were identified. Baseline comorbidities, particularly pulmonary comorbidities, were more common in case subjects than in control subjects (81.1% vs 17.7% for COPD; 44.6% vs 0.6% for bronchiectasis). All-cause hospitalization was observed in 65.7% of case subjects and 44.9% of control subjects. Unadjusted annual hospitalization rates were significantly (P < .05) greater among case subjects than control subjects. Case subjects also had a significantly shorter time to hospitalization than control subjects. The increased burden due to hospitalization was reflected in multivariate analysis adjusting for baseline comorbidities. All-cause hospitalization in patients with NTM-PD relative to control subjects was 1.2 times more likely (relative risk, 1.23; 95% CI, 1.21-1.25; P < .0001) with a 46% greater hazard (hazard ratio, 1.46; 95% CI, 1.43-1.50; P < .0001).

Interpretation: Patients with NTM-PD were significantly more likely to be hospitalized, had greater annualized hospitalization rates, and had shorter time to hospitalization than age- and sex-matched control subjects without NTM-PD. These findings highlight the significantly increased burden of hospitalizations among patients with NTM-PD.

Citing Articles

Prevalence of Chronic Obstructive Pulmonary Disease in Patients with Nontuberculous Mycobacterial Pulmonary Disease: A Systemic Review and Meta-Analysis.

Lee H, Jang J, Kim Y, Min K, Ahn J, Yoo K J Pers Med. 2024; 14(11).

PMID: 39590581 PMC: 11595912. DOI: 10.3390/jpm14111089.


Incremental mortality associated with nontuberculous mycobacterial lung disease among US Medicare beneficiaries with chronic obstructive pulmonary disease.

Wang P, Marras T, Hassan M, Chatterjee A BMC Infect Dis. 2023; 23(1):749.

PMID: 37914999 PMC: 10619258. DOI: 10.1186/s12879-023-08689-9.


Identifying potentially undiagnosed nontuberculous mycobacterial lung disease among patients with chronic obstructive pulmonary disease: Development of a predictive algorithm using claims data.

Wang P, Marras T, Allison P, Hassan M, Chatterjee A J Manag Care Spec Pharm. 2023; 29(8):927-937.

PMID: 37243674 PMC: 10397327. DOI: 10.18553/jmcp.2023.22417.

References
1.
Winthrop K, Baxter R, Liu L, McFarland B, Austin D, Varley C . The reliability of diagnostic coding and laboratory data to identify tuberculosis and nontuberculous mycobacterial disease among rheumatoid arthritis patients using anti-tumor necrosis factor therapy. Pharmacoepidemiol Drug Saf. 2011; 20(3):229-35. PMC: 4094092. DOI: 10.1002/pds.2049. View

2.
OConnell M, Birkenkamp K, Kleiner D, Folio L, Holland S, Olivier K . Lung manifestations in an autopsy-based series of pulmonary or disseminated nontuberculous mycobacterial disease. Chest. 2011; 141(5):1203-1209. PMC: 3342780. DOI: 10.1378/chest.11-0425. View

3.
Hill A . The Quest for Systematic Epidemiology of Nontuberculous Mycobacterial Lung Disease in the United States: Closing in on an Elusive Goal. Ann Am Thorac Soc. 2020; 17(2):169-172. DOI: 10.1513/AnnalsATS.201911-846ED. View

4.
Mehta M, Marras T . Impaired health-related quality of life in pulmonary nontuberculous mycobacterial disease. Respir Med. 2011; 105(11):1718-25. DOI: 10.1016/j.rmed.2011.08.004. View

5.
Novosad S, Henkle E, Schafer S, Hedberg K, Ku J, Siegel S . Mortality after Respiratory Isolation of Nontuberculous Mycobacteria. A Comparison of Patients Who Did and Did Not Meet Disease Criteria. Ann Am Thorac Soc. 2017; 14(7):1112-1119. PMC: 5566290. DOI: 10.1513/AnnalsATS.201610-800OC. View